Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)

被引：18
|
作者：
Niemann, Louisa [1 ]
Lezius, Susanne [2 ]
Maceski, Aleksandra [3 ]
Leppert, David [3 ]
Englisch, Catrin [1 ]
Schwedhelm, Edzard [4 ,5 ]
Zeller, Tanja [5 ,6 ]
Gerloff, Christian [1 ]
Kuhle, Jens [7 ,8 ,9 ]
Choe, Chi-un [1 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Inst Med Biometry & Epidemiol, Hamburg, Germany
[3] Univ Hosp Basel, Dept Biochem, Basel, Switzerland
[4] Univ Med Ctr Hamburg Eppendorf, Inst Clin Pharmacol & Toxicol, Hamburg, Germany
[5] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Luebeck, Hamburg, Germany
[6] Univ Med Ctr Hamburg Eppendorf, Clin Cardiol, Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany
[7] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, MS Ctr, Basel, Switzerland
[8] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Dept Biomed, Basel, Switzerland
[9] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Dept Clin Res, Basel, Switzerland
来源：
PARKINSONISM & RELATED DISORDERS | 2021年 / 90卷
关键词：
UPDRS; Hoehn&Yahr; MOCA; Biomarker; NT-proBNP; motor decline; Cognitive decline; DEFICIENCY; HEART;
D O I：
10.1016/j.parkreldis.2021.07.028
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Introduction: Serum neurofilament light chain (NfL) levels are associated with disease severity in early Parkinson's disease (PD). We assessed the association of serum NfL with motor and cognitive function and decline in advanced PD patients. Methods: NfL concentrations were analyzed with single molecule array (Simoa) assay in serum of 289 PD patients with advanced disease from the single-center prospective observational biobank study Biomarkers in Parkinson's disease (MARK-PD). Motor and cognitive symptoms were assessed with MDS-UPDRS III, Hoehn&Yahr stages and Montreal Cognitive Assessment (MoCA) at baseline and during 520 [364, 674] days of follow-up. Results: Serum NfL concentrations were associated with Hoehn&Yahr stages. During follow-up, baseline NfL levels were associated with time to cognitive decline in adjusted Cox regression models (hazard ratio: 3.23; 95% CI [1.16, 9.00], P < 0.025). Serum NfL was associated with NT-proBNP in adjusted models linking neuronal and cardiac damage in advanced PD patients. Conclusion: In advanced PD patients, serum NfL concentrations are associated with motor function, cognitive decline and subclinical cardiac damage.
引用
收藏
页码：44 / 48
页数：5
相关论文
共 50 条
  • [31] Corpus callosum damage and motor function in Parkinson's disease
    Galantucci, S.
    Agosta, F.
    Stankovic, I.
    Petrovic, I.
    Stojkovic, T.
    Kostic, V. S.
    Filippi, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 120 - 120
  • [32] Brain metabolic pattern (BMP) of cognitive decline in Parkinson's disease (PD)
    Rodriguez, M. C.
    Garcia, D. Garcia
    Clavero, P.
    Lamet, I.
    Irurzun, C.
    Martinez-Lage, P.
    Arbizu, J.
    Prieto, E.
    Obeso, J. A.
    [J]. MOVEMENT DISORDERS, 2008, 23 (01) : S91 - S92
  • [33] Corpus callosum damage and motor function in Parkinson's disease
    Galantucci, S.
    Agosta, F.
    Stankovic, I.
    Petrovic, I.
    Stojkovic, T.
    Kostic, V. S.
    Filippi, M.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S86 - S87
  • [34] Corpus callosum damage and motor function in Parkinson's disease
    Galantucci, S.
    Agosta, F.
    Stankovic, I.
    Petrovic, I.
    Stojkovic, T.
    Comi, G.
    Kostic, V. S.
    Filippi, M.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 : S29 - S29
  • [35] Prospective study of smoking and decline in cognitive function in Parkinson's disease
    Weisskopf, MG
    Grodstein, F
    Ascherio, A
    [J]. NEUROLOGY, 2006, 66 (05) : A214 - A214
  • [36] Prospective study of smoking and decline in cognitive function in Parkinson's disease
    Weisskopf, MG
    Grodstein, F
    Ascherio, A
    [J]. MOVEMENT DISORDERS, 2006, 21 : S103 - S103
  • [37] Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia
    Gonzalez, Maria Camila
    Tovar-Rios, Diego Alejandro
    Alves, Guido
    Dalen, Ingvild
    Williams-Gray, Caroline H.
    Camacho, Marta
    Forsgren, Lars
    Backstrom, David
    Lawson, Rachael A.
    Macleod, Angus D.
    Counsell, Carl E.
    Paquet, Claire
    DeLena, Carlo
    D'Antonio, Fabrizia
    Pilotto, Andrea
    Padovani, Alessandro
    Blanc, Frederic
    Falup-Pecurariu, Cristian
    Lewis, Simon J. G.
    Rejdak, Konrad
    Papuc, Ewa
    Hort, Jakub
    Nedelska, Zuzana
    O'Brien, John
    Bonanni, Laura
    Marquie, Marta
    Boada, Merce
    Pytel, Vanesa
    Abdelnour, Carla
    Alcolea, Daniel
    Beyer, Katrin
    Tysnes, Ole-Bjorn
    Aarsland, Dag
    Maple-Grodem, Jodi
    [J]. MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (06): : 980 - 986
  • [38] Modifiable factors and progression of motor symptoms and cognitive decline in Parkinson's disease
    Forbes, E.
    Tropea, T.
    Mantri, S.
    Morley, J.
    [J]. MOVEMENT DISORDERS, 2019, 34 : S349 - S350
  • [39] Cognitive and Motor Aspects of Parkinson's Disease Associated with Dysphagia
    Kim, Ji Sun
    Youn, Jinyoung
    Suh, Mee Kyung
    Kim, Tae-Eun
    Chin, Juhee
    Park, Suyeon
    Cho, Jin Whan
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2015, 42 (06) : 395 - 400
  • [40] A 14-YEAR LONGITUDINAL STUDY OF THE LEVODOPA MOTOR RESPONSE IN PARKINSON'S DISEASE: EFFECTS OF COGNITIVE DECLINE ON MOTOR FUNCTION
    Alty, J. E.
    Clissold, B. G.
    McColl, C. D.
    Reardon, K. R.
    Shiff, M.
    Kempster, P. A.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (04): : 460 - 461
12345